Getting a lot of questions about vaccines and variants and why @moderna_tx is developing a booster based on variant discovered in South Africa if vaccines are thought to protect against it.
So a quick thread.
And story is up here: sciencemag.org/news/2021/01/v…
@moderna_tx First of all, there are several ways in which new variants can worsen the situation:
They can be deadlier, more transmissible or more likely to infect people who have been infected already or received vaccines - or, of course, a combination of these.
@moderna_tx The biggest problem for the world RIGHT NOW are variants with increased transmissibility, because that means measures have to be stricter for the virus not to spread and if it does spread it means more disease and death before the world is vaccinated.
@moderna_tx But variants better able to escape immunity are important too and it is important here to distinguish between the situation now and what it means for the future.
@moderna_tx Right now, we have data showing that the virus has escaped immunity from some monoclonal antibodies.
This is not surprising: a monoclonal antibody is like that opponent in chess who always makes the same move.
It is easy to adapt to.
@moderna_tx This new preprint by David Ho’s group shows that 501Y.V2 already "is resistant to a major group of potent mAbs ..., including two authorized for emergency use”. biorxiv.org/content/10.110…
As @JeremyFarrar told me: “We shouldn't be using single monoclonals."
@moderna_tx@JeremyFarrar The immunity humans develop from vaccines or infection is different: It consists of many different antibodies (polyclonal) and on top of that there are T cells.
So what is the picture, right now? I won’t go through it all, since @florian_krammer did so:
@moderna_tx@JeremyFarrar@florian_krammer Short version: Evidence is accumulating that our antibodies are not as good at neutralising the South African variant as previous versions of the virus. Apart from Ho’s paper and the one by Moderna, there is a lot of work from South Africa, including this: medrxiv.org/content/10.110…
@moderna_tx@JeremyFarrar@florian_krammer But: The mRNA vaccines induce such high levels of antibodies that the drop may not matter much.
As @trvrb told me: "Given the high starting point, it’s conceivable [vaccine efficacy] could drop only slightly."
@moderna_tx@JeremyFarrar@florian_krammer@trvrb It’s important to remember that immunity is not black-and-white. For most people the drop in antibody neutralization may not matter, but for some on the margins it could push them into non-protected territory. Or the immunity could wane a little bit faster. We don’t know.
@moderna_tx@JeremyFarrar@florian_krammer@trvrb The other thing we don’t know: How will the virus evolve in the future?
For now the immune escape of the new variants seems to be mainly down to one mutation: E484K (again, read Ho’s paper).
“E484K is really the bad boy here,” @stgoldst told me.
@moderna_tx@JeremyFarrar@florian_krammer@trvrb@stgoldst The P.1 variant (spreading in Manaus) carries the same E484K mutation. Is that because the virus does not have that many ways to escape antibodies? Or does it have a lot of tricks and nasty surprises left? We just don’t know.
@moderna_tx@JeremyFarrar@florian_krammer@trvrb@stgoldst That is why preparing for variants that are even better at evading immunity is the right thing to do RIGHT NOW.
Moderna working on a third shot that could boost antibody levels is a good start because it will undoubtedly teach the company a lot about how that strategy works.
@moderna_tx@JeremyFarrar@florian_krammer@trvrb@stgoldst But it’s not just science, but also questions of regulatory approval, production etc. As @angie_rasmussen told me: "It’s also wise to begin thinking about how they will be distributed." For example: Will they be allocated to regions where the escape variants are circulating?
Just listened to a fascinating webinar by @ShabirMadh presenting the results from Novavax trial in South Africa and UK.
So will turn this into a brief thread to give some context on what we know so far and what the trial results (probably) mean:
First of all, this vaccine uses a more traditional approach than the mRNA vaccines we have been talking about a lot: It essentially consists of particles studded with the crucial spike protein plus an adjuvant to induce a potent immune response.
The study: This was a phase 2 study with just over 4400 participants and initially designed to look at HIV- people only. @ShabirMadh says they had “ to really work hard to get Novavax and everyone else to agree to do a sample of HIV-infected individuals”, which is crucial in SA.
“The world is at a critical juncture. With the emergence of new, more transmissible variants globally ... every country is now at risk of returning to square one unless we redouble our efforts to supress #Covid19 everywhere”, says @JeremyFarrar in new statement.
@JeremyFarrar “Vaccine nationalism doesn’t serve anyone. At the moment, vaccines are in short supply. But the new variants are an urgent warning of what is coming… .
It is in the national interest of all countries to bring infections down globally as much as possible."
@JeremyFarrar “Vaccinating a lot of people in a few countries, leaving the virus unchecked in large parts of the world, will lead to more variants .... The more that arise, the higher the risk of the virus evolving to an extent where our vaccines, treatments and tests are no longer effective."
"A year ago today, fewer than 1500 cases of #COVID19 had been reported to @WHO, including just 20 cases outside China”, says @DrTedros at WHO presser. "This week, we expect to reach 100 million reported cases.”
@WHO@DrTedros "Numbers can make us numb to what they represent: every death is someone’s parent, someone’s partner, someone’s child, someone’s friend”, says @drtedros. "Vaccines are giving us hope, which is why every life we lose now is even more tragic."
@WHO@DrTedros "Last week, I said that they will distribute on the brink of a catastrophic moral failure if it doesn't deliver equitable access to vaccines”, says @DrTedros. "Two new studies show that it wouldn't just be a moral failure. It would be an economic failure."
New @ECDC_EU risk assessment on variants of concern says likelihood of them spreading in Europe is very high, likely leading to more transmission and death. “Stricter NPIs are needed to reduce transmission and relieve the pressure on healthcare systems.”
Detection:
- “Member States need to increase the level of surveillance and sequencing of a representative sample of community #COVID19 cases”
- “Member States should prepare laboratories for a higher demand for testing”
Curbing transmission:
- compliance with stricter non-pharmaceutical interventions than those currently implemented, and strengthened case detection with contact tracing
- non-essential travel should be avoided
- accelerate vaccination of high-risk groups
Today’s presentation from South Africa on 501Y.V2 (the second variant of concern in case you've lost count) is very interesting.
Regrettably it only adds to concerns about potential immune escape from this variant:
When convalescent sera from 44 people infected in first wave in South Africa was confronted with 501Y.V2, antibodies from 21 out of 44 did not recognize the variant.
Important to remember that our immunity is not just due to antibodies, but also T cells. So fingers crossed!
There are other caveats: Vaccine- induced immunity may be very different from natural immunity, for instance.
This is just one data point, but as so often in the last weeks I would have preferred different data 🤷♂️
Situation with new #sarscov2 variants is becoming harder to follow (and not just because of the names), so let me try and give a brief overview: Where are we at? What should we be worried about? And how worried?
For now there are three variants with sufficient evidence for scientists to be really concerned and I‘ll start with the newest one: P.1.
This was described on Tuesday from December samples from Manaus and had already been picked up in Japan in travelers. virological.org/t/genomic-char…
Why is it concerning? Three main reasons: 1. The place: P.1 is spreading in Manaus, which is experiencing a devastating surge after already experiencing a terrible wave of infections in March/April. @DrMikeRyan described the dire situation yesterday: